Foventa's Rebrand Is About the Money Question

Exonate has renamed itself Foventa Therapeutics. If you were looking to buy shares in it, you'd be out of luck: the company isn't publicly traded. There is no ticker, no market cap, and no price chart.

Which is worth knowing before anything else. Most biotech stories that land on investment desks are about stocks you can own. This one isn't. It is, though, an example of how a small private company tries to build itself into something a larger company might want to acquire — and the rebrand is one piece of that machinery.

The company, based in Cambridge and Nottingham, England, has been working since 2016 on something that sounds too convenient to be true: an eye drop that could treat diabetic retinopathy. The current standard of care for advanced diabetic eye disease is intravitreal injections — needles into the eyeball, every few weeks, indefinitely. An eye drop that actually reached the retina would be a different experience for patients. It would also be a different kind of product, one that ophthalmologists and pharmaceutical companies would treat differently.

That is what the name change is pointing toward. The new name comes from "fovea" — the tiny center of the retina responsible for sharp, detailed vision — and it signals a narrower focus. Under the old name, Exonate presented itself as a discovery science company with a platform for inhibiting SRPK1, an enzyme involved in how cells splice their mRNA. That platform work was interesting but not, by itself, investable. The new identity is around one compound, FOV407 (formerly EXN407), and one disease: non-proliferative diabetic retinopathy, or NPDR.

That shift from platform to program is worth paying attention to because it tells you about the company's capital situation and what it needs next.

The compound is a small-molecule SRPK1 inhibitor. The mechanism is specific: it modulates how vascular endothelial growth factor (VEGF) mRNA is spliced, selectively reducing the pro-angiogenic isoforms that drive abnormal blood vessel growth in the retina. Instead of blocking VEGF directly like anti-VEGF injection drugs (Eylea, Lucentis, Beovu), it changes the cell's production of the more harmful VEGF variants. And it is designed to penetrate through the eye's layers so it can be applied topically.

That last part is the hard bit. The eye is defended by multiple barriers — the cornea, the conjunctiva, the sclera — that keep most drops from reaching the back of the eye where the retina lives. Getting a drug molecule through those barriers by drops alone is why this problem hasn't been solved in decades. The company says it selected FOV407 from over 1,000 designed and synthesized molecules for its retinal penetration properties.

The early clinical data, from a Phase Ib/IIa trial released in March 2024, showed that the drops actually do something inside the eye. In the trial, 60% of patients treated with EXN407 showed a reduction in vascular leakage, compared to 20% in the control group. A published analysis reported an odds ratio of 7.4 with statistical significance, and the company noted no drug-related serious adverse events. Patient compliance was high, which matters for a twice-daily topical treatment.

These are Phase Ib/IIa numbers, from a small exploratory study. They are signals, not proof. But they are the kind of signals that get you to the next gate.

And the next gate is a Phase IIb trial called CLEAR-DE, which was planned for early 2026. That trial will enroll 140 patients across sites in Australia, the Middle East, and China, evaluating clinical efficacy, optimal dosing, and safety in NPDR patients. The trial design has already been validated through a Type C meeting with the FDA — a regulatory discussion that gives companies a sense of whether the FDA would accept the trial's results.

Here is where the money question gets sharp. A Phase IIb trial across multiple international sites is expensive. The company's total disclosed funding to date is around $7.74 million, raised across angel rounds starting in 2016, plus a £4.9 million Wellcome Trust grant and a £1.5 million round from angel investors. That is discovery money, not Phase IIb money.

The company has been actively seeking strategic partners. It had a collaboration with Janssen Pharmaceuticals (part of Johnson & Johnson) announced in January 2020, but that partnership was for a broader indication — wet age-related macular degeneration and diabetic macular edema — which required intravitreal delivery and competed head-on with billion-dollar anti-VEGF franchises. There is no public record of that collaboration surviving into the NPDR-focused pivot, and the new CEO, Olav Hellebø, took the helm in June 2026 as the company prepares for this phase of development. Hellebø comes from big pharma, with over 30 years of experience in pharmaceutical development. He is the kind of hire you make when you need to close a partner deal.

So the picture is: a private company with a promising signal from a small trial, entering the expensive phase of development, without an obvious funding partner yet. The rebrand to Foventa, the fovea, sharper vision — it is the kind of identity refresh a company does when it is about to walk through a partner's door and needs to look like a company with one clear mission, not a research lab with ideas.

Why should a pharmaceutical company care? The answer is the NPDR market, and the gap in current treatment.

Diabetic retinopathy affects roughly one-third of the nearly 500 million people with diabetes globally. NPDR is the earlier stage of the disease. Currently, there are no FDA-approved medications for NPDR. The standard of care is observation and optimization of blood sugar, blood pressure, and cholesterol — good general health management, but no drug that slows the disease itself. Anti-VEGF injections are approved for the later stages, once macular edema or proliferative changes appear, by which time some damage may already be done.

A topical treatment for NPDR would open a market that is, essentially, untreated. It would also sit upstream of the injection market — treating earlier, preventing progression, and potentially reducing the number of patients who eventually need injections. The broader diabetic retinopathy treatment market was valued at roughly $9 billion in 2023 and is projected to grow. But the NPDR-specific addressable market is the unpriced portion — the patients who currently receive no pharmaceutical treatment at all.

That is an attractive profile for a pharmaceutical acquirer. A drug that can be self-administered at home, taken twice daily, with demonstrated safety and a signal of efficacy, targeting hundreds of millions of patients — it checks boxes that partner companies look for. The question is whether Phase IIb data will be strong enough to make those boxes compelling.

There is competition here, though not from approved products. Other companies are developing topical approaches for diabetic eye disease, including integrin inhibitors and other modalities. The field is crowded enough that a partner will want to see differentiation, but empty enough that no one has yet claimed the space.

The rebrand itself is not a financial transaction. It doesn't create value the way a partnership deal or a positive Phase III readout would. But it does mark a transition point — the moment the company stops identifying as a science platform and starts identifying as a product company with a clear commercial pathway. In biotech terms, that is often the transition from "interesting science" to "acquirable asset," and it is the hardest transition in a small company's life.

For readers who want to track the outcome: since Foventa is private, there is no stock to watch. The next meaningful event will be the Phase IIb CLEAR-DE trial results. Those results will tell you whether an eye drop can do inside the eye what injections do — and whether a small Cambridge company has built something that a large pharmaceutical company is willing to buy.